Please upgrade your browser.
Personalized treatment plans may extend life expectancy for early-stage kidney cancer patients who have risk factors for worsening kidney disease, according to a new study published in the journal Radiology.
European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Yesterday, Bristol-Myers Squibb announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (“low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).
VEGF TKIs have long defined the frontline standard of care in metastatic renal cell carcinoma (mRCC), but several promising trials evaluating their use in combination with immunotherapy agents may redefine the frontline setting in this patient population.
Royal jelly, a substance secreted by worker honeybees that is the exclusive food for queen bees, may ease the adverse effects of tyrosine kinase inhibitor (TKI) therapy for advanced renal cell carcinoma (RCC).
A clinical trial in the U.K. has just launched to assess the effectiveness of a newly developed breath test that could help diagnose multiple forms of cancer, including kidney cancer.
Looking to enroll in a clinical trial? Check out this list from the National Cancer Institute.
The rate of people dying from cancer in the United States seems to have dropped steadily for 25 years, a new study says, but disparities remain between the rich and the poor. The overall nationwide cancer death rate fell continuously from 1991 to 2016 by a total of 27%, according to a study by the American Cancer Society, published Tuesday in CA: A Cancer Journal for Clinicians.
There's an effort underway to make a new atlas of all the cells in the human body and to describe each cell type using all the powerful tools of today's genetic technology. The study will take quite a few years to complete but scientists say the payoff will be huge. Through this study, they are hoping to gain new insights into many different diseases such as cancer.
This study discusses stereotactic radiosurgery for multiple brain metastases from renal-cell carcinoma.
Obesity, hypertension and smoking are the three modifiable risk factors that could aggressively be targeted to reduce renal cell carcinoma, according to a new study that was done by the University of Texas Health Science Center and the South Texas Veterans Healthcare System.
|Powered by NeonCRM|